These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31853617)

  • 1. cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development.
    Friebe A; Sandner P; Schmidtko A
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):287-302. PubMed ID: 31853617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting report.
    Friebe A; Kraehling JR; Russwurm M; Sandner P; Schmidtko A
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Aug; 396(8):1669-1686. PubMed ID: 37079081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
    Kopra K; Sharina I; Martin E; Härmä H
    Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meeting report of the 8
    Friebe A; Sandner P; Schmidtko A
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1177-1188. PubMed ID: 29018913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Guanylate Cyclase Stimulators and Activators.
    Sandner P; Zimmer DP; Milne GT; Follmann M; Hobbs A; Stasch JP
    Handb Exp Pharmacol; 2021; 264():355-394. PubMed ID: 30689085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
    Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
    Sandner P; Berger P; Zenzmaier C
    Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
    Sandner P
    Biol Chem; 2018 Jun; 399(7):679-690. PubMed ID: 29604206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
    Hoffmann LS; Chen HH
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Aug; 387(8):707-18. PubMed ID: 24927824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cGMP becomes a drug target.
    Schlossmann J; Schinner E
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Mar; 385(3):243-52. PubMed ID: 22297800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble guanylyl cyclase: more secrets revealed.
    Pyriochou A; Papapetropoulos A
    Cell Signal; 2005 Apr; 17(4):407-13. PubMed ID: 15601619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications.
    Chen Y; Burnett JC
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29584705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
    Xiao S; Li Q; Hu L; Yu Z; Yang J; Chang Q; Chen Z; Hu G
    Mini Rev Med Chem; 2019; 19(18):1544-1557. PubMed ID: 31362687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.
    Bice JS; Burley DS; Baxter GF
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):269-82. PubMed ID: 24572031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. sGC-cGMP signaling: target for anticancer therapy.
    Bian K; Murad F
    Adv Exp Med Biol; 2014; 814():5-13. PubMed ID: 25015797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of cGMP in heart failure: a new therapeutic paradigm.
    Boerrigter G; Lapp H; Burnett JC
    Handb Exp Pharmacol; 2009; (191):485-506. PubMed ID: 19089342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation, signaling functions, and metabolisms of nitrated cyclic nucleotide.
    Sawa T; Ihara H; Ida T; Fujii S; Nishida M; Akaike T
    Nitric Oxide; 2013 Nov; 34():10-8. PubMed ID: 23632125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular cGMP-generating systems in physiological and pathological conditions.
    Cerra MC; Pellegrino D
    Curr Med Chem; 2007; 14(5):585-99. PubMed ID: 17346149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.